REFFERENCES
- Feig , D. I. , Kang , D. H. and Johnson , R. J. 2008 . Uric acid and cardiovascular risk . N. Engl. J. Med. , 359 : 1811 – 1821 .
- Athyros , V. G. , Elisaf , M. , Papageorgiou , A. A. , Symeonidis , A. N. , Pehlivanidis , A. N. , Bouloukos , V. I. , Milionis , H. J. and Mikhailidis , D. P. 2004 . Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study . Am. J. Kidney. Dis. , 43 : 589 – 599 .
- Milionis , H. J. , Rizos , E. , Kostapanos , M. , Filippatos , T. D. , Gazi , I. F. , Ganotakis , E. S. , Goudevenos , J. , Mikhailidis , D. P. and Elisaf , M. S. 2006 . Treating to target patients with primary hyperlipidemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) . Curr. Med. Res. Opin. , 22 : 1123 – 1131 .
- Huggins , G. S. , Pasternak , R. C. , Alpert , N. M. , Fischman , A. J. and Gewirtz , H. 1998 . Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse . Circulation , 98 : 1291 – 1296 .